Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 217

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer

Open access
Nordström, Tobias, Vickers, Andrew, Assel, Melissa, Lilja, Hans, Grönberg, Henrik, Eklund, Martin · 2015 · European Urology

Abstract

BACKGROUND The four-kallikrein panel and the Prostate Health Index (PHI) have been shown to improve prediction of prostate cancer compared to prostate-specific antigen (PSA). No comparison between the four-kallikrein panel and PHI has been presented. OBJECTIVE To compare the four-kallikrein panel to PHI for predicting prostate cancer in an independent cohort. DESIGN, SETTING AND PARTICIPANTS Participants were from a population-based cohort of PSA-tested men in Stockholm County. We included men (n=531) with PSA 3–15 ng/ml undergoing first-time prostate biopsy during 2010–2012. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Models were fitted to case status. We computed calibration curves, the area under the receiver-operating characteristics curve (AUC), decision curves, and percent saved biopsies. RESULTS AND LIMITATIONS The four-kallikrein panel showed AUCs of 69.0 when predicting any-grade prostate cancer and 71.8 when predicting high-grade cancer (≥Gleason 7). Similar values were found for PHI: 70.4 and 71.1, respectively. Both models had higher AUC than a base model with PSA and age (p<0.0001 for both); differences between models were not significant. Sensitivity analyses including men with any PSA or a previous biopsy did not materially affect our findings. Using 10% predicted risk of high-grade prostate cancer by the four- kallikrein panel or PHI=39 as cutoff for biopsy saves 29% of performed biopsies to the cost of delayed diagnosis for 10% of the men with high-grade cancers. Both models showed limited net benefit in decision analysis. The main study limitation was lack of digital rectal examination data and biopsy decision being based on PSA information. CONCLUSIONS The four-kallikrein panel and PHI similarly improved discrimination when predicting prostate cancer and high-grade prostate cancer. Both are simple blood tests that can reduce the number of unnecessary biopsies compared to screening with total PSA, representing an important new option to reduce harm.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2014.08.010

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 217

Metadata

Authors
Nordström, T., Vickers, A., Assel, M., Lilja, H., Grönberg, H., & Eklund, M.
Venue
European Urology
Publisher
Elsevier BV
Published
2015-07
Volume
68
Issue
1
Pages
139-146
ISSN
0302-2838 (ISSN-L)
OpenAlex
W2088978840
Cited by
217
References
2
FWCI
14.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2014.08.010
The paper
Nordström, T., Vickers, A., Assel, M., Lilja, H., Grönberg, H., & Eklund, M. (2015). Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2014.08.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.